BERKELEY, CA., April 18, 2022 /PRNewswire/ — Bakar Labs, the incubator at UC Berkeley’s Bakar BioEnginuity Hub (BBH), today announced a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies to treat cystic fibrosis. The CF Foundation is sponsoring a “Golden Ticket” competition in the new incubator and is encouraging companies with emerging technologies in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply. Applications open Monday, May 2nd.
Laboratory space and facilities at Bakar Labs will be provided for up to three potential winners. In addition to laboratory and office space, companies have access to the extensive resources of the CF Foundation, including scientific experts and advice, laboratory/research tools and techniques, an extensive patient registry, clinical trial design support, and a Therapeutics Development Network of over 90 centers for clinical studies in the USA.
“Collaborating with the CF Foundation is fully in line with the spirit of entrepreneurship for the benefit of society,” he said Regis KellyPhD, OBE, Director of Bakar Labs and CEO of QB3, the University of California Entrepreneurship Institute, which has a partnership with Berkeley to start BBH. “Our dual bottom line at Bakar Labs emphasizes public good on an equal footing with profit potential.”
“This collaboration is inspiring,” he said David Schaffer, PhD, Managing Director of BBH. “Students and professors will see the potential of entrepreneurship fused with the resources and mission of a large patient advocacy organization. It will be a great example that could spur partnerships in a variety of areas.” Schaffer is the Hubbard Howe Distinguished Professor at UC Berkeley, with appointments in the departments of Chemical and Biomolecular Engineering, Bioengineering, and Molecular and Cellular Biology.
“Working with the CF Foundation creates an extraordinary opportunity,” said Gino Segrè, PhD, Managing Director of Bakar Labs. “We will raise awareness of a devastating condition and provide special resources that will inspire and support a community of researchers and entrepreneurs to apply their breakthrough ideas to the development of a cure. We are pleased that Bakar Labs is now a proving ground for major advances.”
A focus on entrepreneurship for the greater good is now widely seen by many philanthropists and investors as a valuable and effective complement to their academic scholarship support. The CF Foundation has won worldwide admiration for its support of disease-related research efforts, not only from scientists in academic laboratories but also from entrepreneurs in start-up companies.
For more information, visit the CF Foundation’s Golden Ticket page on the Bakar Labs website or contact us [email protected].
About the Bakar BioEnginuity Hub
The Bakar BioEnginuity Hub empowers intrepid founders – and aspiring founders – to create bold solutions to our world’s most pressing problems. Focused on people working on the convergence of life sciences with physical, engineering and data sciences, the Bakar BioEnginuity Hub provides the intellectual, entrepreneurial and community resources needed to learn and then launch their own ventures. The Bakar BioEnginuity Hub is located on the UC Berkeley campus in the stunning Woo Hon Fai Hall. Visit bioenginuityhub.berkeley.edu.
About Bakar Labs
Bakar Labs is the flagship life sciences-focused incubator at UC Berkeley’s Bakar BioEnginuity Hub. Operated by QB3, Bakar Labs offers extensive equipment, laboratory and office facilities, and a community of like-minded entrepreneurs to help startups grow. Bakar Labs can support up to 50 early stage companies from around the world focused on delivering life science innovations that promise to improve human health. No UC affiliation is required to join. Visit bakarlabs.berkeley.edu for information on how to join or form a partnership.
SOURCE Bakar Labs